Sıçanlarda deneysel omurilik hasarında tocilizumabin nöral dokuda iyileşme üzerine etkileri
Küçük Resim Yok
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Düzce Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Sitokinler, organizmada immün sistemin düzenlenmesinde ve proinflamatuar-inflamatuar süreçlerde önemli rol oynayan moleküllerdir. Yabancı antijen ve ajanlara karşı Sitokinler lokal ve sistemik inflamatuar reksiyonlarda rol alırlar. Sitokinlerin önemli bir bölümü interlökinlerdir. İnterlökin (IL)-6 ilk olarak preaktivasyon halindeki normal insan lenfositleri tarafından immünglobülin salgılatan bir faktör olarak tanımlanmıştır. IL-6 reseptörü membranda olan (IL-6R) ve çözünür (sIL-6R) olmak üzere 2 formdadır. Tosilizumab bu reseptörlere bağlanarak IL-6'nın rol aldığı sinyalizasyon ve inflamasyon sürecini inhibe eder. Bu çalışmada tosilizumab tedavisinin akut omurilik yaralanması (AOY) ile oluşan hasarda nöral doku üzerinde olumlu etkisinin olup olmadığının değerlendirilmesi amaçlanmıştır. Çalışmada deney ortamındaki düzenek yardımıyla sıçanlarda omurilik hasarlanması oluşturulmuş, omurilikte hasar oluşturduktan sonra sıçanlara düşük ve yüksek doz tosilizumab intraperitoneal olarak verilmiştir. Tosilizumab tedavisinin sonunda 8. günde sıçanlar sakrifiye edilerek patolojik inceleme için gönderilmiştir. Sonuçlar omuriliği hasarlanmış tosilizumab verilmeyen ve metil prednizolon verilen sıçanların sonuçları ile karşılaştırılmıştır. Eğik düzlem, Drummond ve Moore Kriterleri, Hemotoksilen-eozin ve Cleaved caspase 3 immunohistokimyasal boyamasının sonuçlarına göre tosilizumab AOY ile oluşan hasarın giderilmesinde etkili bulunmuştur. Tedavi dozu yükseldiğinde bu etkinin arttığı izlenmiştir. Tosilizumabın AOY tedavisinde faydalı olabileceği görülmüştür. Ancak daha geniş serilerde yapılmış klinik ve laboratuar çalışmalarıyla bulguların desteklenmesi gerekmektedir. Anahtar Kelimeler: Tosilizumab, Akut omurilik yaralanması, Anti inflamatuvar, İnterlökin (IL)-6, Metil prednizolon
Cytokines are molecules that play an important role in then regulation of the immüne system and proinflammatory-inflammatory processes in the organism. Cytokines are in volved in local and systemic inflammatory reactions against foreign antigens and agents. An important part of cytokines are interleukins. Interleukin (IL)-6 was first identified as an immunoglobulin-secreting factor by preactivated normal human lymphocytes. The IL-6 receptor exists in two forms: membrane (IL-6R) and soluble (sIL-6R). Tocilizumab binds to these receptors and inhibits the signal ingand inflammation processes in which IL-6 is involved. In this study, it was aimed to evaluate whether tocilizumab treatment has a positive effect on the neural tissue in the injury caused by acute spinal cord injury (ASCİ). In the study, spinal cord injury was created in rats with the help of the apparatus in the experimental environment, and low and high doses of tocilizumab were administered intraperitoneally to the rats after causing damage to the spinal cord. At the end of the tocilizumab treatment, on the 8th day, the rats were sacrificed and sent fo rpathological examination. The results were compared with the results of spinal cord injured rats not given tocilizumab and given methyl prednisolone. According to the results of inclined plane, Drummond and Moore Criteria, Hemotoxylin-eosin, Luxolfast and Cleavedcaspase 3 immunohistochemicalstaining, tocilizumab was found to be effective in removing the damage caused by ASCİ. It was observed that this effect increased when the treatment dose was increased. It has been observed that tocilizumab may be beneficial in thetreatment of ASCİ.However, the findings need to be supported by clinical and laboratory studies conducted in larger series. KEY WORDS: Tocilizumab, Acute spinal cord injury, Anti-inflammatory, Interleukin (IL)-6, methylprednisolone
Cytokines are molecules that play an important role in then regulation of the immüne system and proinflammatory-inflammatory processes in the organism. Cytokines are in volved in local and systemic inflammatory reactions against foreign antigens and agents. An important part of cytokines are interleukins. Interleukin (IL)-6 was first identified as an immunoglobulin-secreting factor by preactivated normal human lymphocytes. The IL-6 receptor exists in two forms: membrane (IL-6R) and soluble (sIL-6R). Tocilizumab binds to these receptors and inhibits the signal ingand inflammation processes in which IL-6 is involved. In this study, it was aimed to evaluate whether tocilizumab treatment has a positive effect on the neural tissue in the injury caused by acute spinal cord injury (ASCİ). In the study, spinal cord injury was created in rats with the help of the apparatus in the experimental environment, and low and high doses of tocilizumab were administered intraperitoneally to the rats after causing damage to the spinal cord. At the end of the tocilizumab treatment, on the 8th day, the rats were sacrificed and sent fo rpathological examination. The results were compared with the results of spinal cord injured rats not given tocilizumab and given methyl prednisolone. According to the results of inclined plane, Drummond and Moore Criteria, Hemotoxylin-eosin, Luxolfast and Cleavedcaspase 3 immunohistochemicalstaining, tocilizumab was found to be effective in removing the damage caused by ASCİ. It was observed that this effect increased when the treatment dose was increased. It has been observed that tocilizumab may be beneficial in thetreatment of ASCİ.However, the findings need to be supported by clinical and laboratory studies conducted in larger series. KEY WORDS: Tocilizumab, Acute spinal cord injury, Anti-inflammatory, Interleukin (IL)-6, methylprednisolone
Açıklama
Anahtar Kelimeler
Nöroşirürji, Neurosurgery
